The latest price target for Virpax Pharmaceuticals (NASDAQ:VRPX) was reported by Maxim Group on October 9, 2024. The analyst firm set a price target for $0.00 expecting VRPX to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Virpax Pharmaceuticals (NASDAQ:VRPX) was provided by Maxim Group, and Virpax Pharmaceuticals downgraded their hold rating.

The last upgrade for Virpax Pharmaceuticals Inc happened on July 19, 2024 when Maxim Group raised their price target to $3. Maxim Group previously had a hold for Virpax Pharmaceuticals Inc.

The last downgrade for Virpax Pharmaceuticals Inc happened on October 9, 2024 when Maxim Group changed their price target from N/A to N/A for Virpax Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Virpax Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Virpax Pharmaceuticals was filed on October 9, 2024 so you should expect the next rating to be made available sometime around October 9, 2025.

While ratings are subjective and will change, the latest Virpax Pharmaceuticals (VRPX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Virpax Pharmaceuticals (VRPX) is trading at is $0.60, which is out of the analyst’s predicted range.